Mikrobiom und metabolische Fettlebererkrankung (MeFLD)

Translated title of the contribution: The microbiome and metabolic fatty liver disease (MeFLD)

Noreen Neuwirth, Samuel Kochenburger, Christian Sina*

*Corresponding author for this work


Background: Despite intensive research, both the pathogenesis and the pathophysiology of metabolic fatty liver disease (MeFLD) and its hepatic complications are poorly understood. Dyslipidemias and glucose metabolism disorders are among the well-studied pathomechanisms. In addition, the intestinal microbiome is increasingly suspected to be significantly involved in the occurrence and progression of MeFLD, via the regulation of the metabolism and the immune system. Objectives: The work focuses on the importance of the microbiome in the context of pathogenesis and pathophysiology in MeFLD. Mechanisms of how the microbiome potentially contributes to the development of MeFLD will be highlighted. Materials and methods: A systematic literature search was undertaken using PubMed and forms the basis of this work. Results: The microbiome is involved in the development of MeFLD via numerous mechanisms and signaling pathways. While animal studies show clear evidence for this link, clinical evidence is lacking despite overall promising results. Human intervention studies with prebiotics, probiotics, or synbiotics, as well as fecal microbiome transfer suggest that modulation of the microbiome may be a promising therapeutic option in patients with MeFLD. Conclusion: As our understanding of the influence of the microbiome on the pathogenesis of MeFLD progresses, targeted interventions for prevention and therapy of MeFLD may be adopted in the future.

Translated title of the contributionThe microbiome and metabolic fatty liver disease (MeFLD)
Original languageGerman
Issue number4
Pages (from-to)391-397
Number of pages7
Publication statusPublished - 06.2021

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'The microbiome and metabolic fatty liver disease (MeFLD)'. Together they form a unique fingerprint.

Cite this